ERBB2 and acute lymphoblastic leukemia: To further address specificity for the ErbB2 pathway, clinically relevant doses of the ErbB1/2-specific TKI lapatinib were used which, much like canertinib, abrogated proliferation of ErbB2+Ph+ALL cell lines (Fig. 6B).